Multiple myeloma baseline characteristics based on cardiac events
| . | No cardiac events (N = 67) . | Cardiac events (N = 11) . | P value . |
|---|---|---|---|
| Multiple myeloma subtype | .13 | ||
| Intact immunoglobulin disease | 54 (80.6%) | 6 (54.5%) | |
| Light-chain disease | 13 (19.4%) | 5 (45.5%) | |
| All multiple myeloma LC subtype | .001 | ||
| κ | 53 (79.1%) | 3 (27.3%) | |
| λ | 14 (20.9%) | 8 (72.7%) | |
| Light-chain disease LC subtype | .769 | ||
| κ | 8 (61.5%) | 2 (40.0%) | |
| λ | 5 (38.5%) | 3 (60.0%) | |
| Concomitant amyloidosis | 1 (1.5%) | 0 (0.0%) | 1 |
| High-risk cytogenetics | 17 (25.4%) | 5 (45.5%) | .312 |
| t(11,14) in BM FISH | 4 (6.0%) | 1 (9.1%) | 1 |
| IgH/CCDN1 percentage (t(11;14)) | 0.0 (0.0-0.0) | 0.0 (0.0-34.0) | .141 |
| High BM burden | 20 (29.9%) | 6 (54.5%) | .206 |
| R-ISS stage at CAR-T infusion | < .001 | ||
| I | 16 (24.2%) | 2 (20.0%) | |
| II | 44 (66.7%) | 2 (20.0%) | |
| III | 6 (9.1%) | 6 (60.0%) | |
| Extramedullary disease | 29 (43.3%) | 8 (72.7%) | .137 |
| Prior line of therapy | 6.2±2.4 | 6.0±1.4 | .795 |
| Last dose of carfilzomib (d) | 561.0 ± 566.4 | 401.9 ± 444.9 | .379 |
| Prior autologous HSCT | 53 (79.1%) | 9 (81.8%) | 1 |
| Bridging therapy | 37 (55.2%) | 8 (80.0%) | .255 |
| Prior anti BCMA exposure | 10 (15.4%) | 0 (0.0%) | .361 |
| Refractory status | .021 | ||
| Double refractory | 2 (3.0%) | 3 (27.3%) | |
| Triple refractory | 36 (53.7%) | 4 (36.4%) | |
| Penta refractory | 26 (38.8%) | 4 (36.4%) | |
| Κ LC value (mg/dL) | 76.0 (10.7-446.3) | 1.8 (1.4-12.1) | .013 |
| Λ LC value (mg/dL) | 2.9 (1.6-12.5) | 1048.4 (2.3-1553.2) | .023 |
| Serum M spike value (g/dL) | 0.6 (0.2-1.6) | 0.4 (0.0-2.8) | .657 |
| Baseline ferritin (ng/mL) | 327.0 (90.0-830.5) | 730.0 (502.0-3575.0) | .028 |
| Baseline CRP (μg/mL) | 0.8 (0.2-3.3) | 0.9 (0.7-3.9) | .455 |
| Fluid overload post lymphodepletion | 6 (9.0%) | 2 (18.2%) | .690 |
| . | No cardiac events (N = 67) . | Cardiac events (N = 11) . | P value . |
|---|---|---|---|
| Multiple myeloma subtype | .13 | ||
| Intact immunoglobulin disease | 54 (80.6%) | 6 (54.5%) | |
| Light-chain disease | 13 (19.4%) | 5 (45.5%) | |
| All multiple myeloma LC subtype | .001 | ||
| κ | 53 (79.1%) | 3 (27.3%) | |
| λ | 14 (20.9%) | 8 (72.7%) | |
| Light-chain disease LC subtype | .769 | ||
| κ | 8 (61.5%) | 2 (40.0%) | |
| λ | 5 (38.5%) | 3 (60.0%) | |
| Concomitant amyloidosis | 1 (1.5%) | 0 (0.0%) | 1 |
| High-risk cytogenetics | 17 (25.4%) | 5 (45.5%) | .312 |
| t(11,14) in BM FISH | 4 (6.0%) | 1 (9.1%) | 1 |
| IgH/CCDN1 percentage (t(11;14)) | 0.0 (0.0-0.0) | 0.0 (0.0-34.0) | .141 |
| High BM burden | 20 (29.9%) | 6 (54.5%) | .206 |
| R-ISS stage at CAR-T infusion | < .001 | ||
| I | 16 (24.2%) | 2 (20.0%) | |
| II | 44 (66.7%) | 2 (20.0%) | |
| III | 6 (9.1%) | 6 (60.0%) | |
| Extramedullary disease | 29 (43.3%) | 8 (72.7%) | .137 |
| Prior line of therapy | 6.2±2.4 | 6.0±1.4 | .795 |
| Last dose of carfilzomib (d) | 561.0 ± 566.4 | 401.9 ± 444.9 | .379 |
| Prior autologous HSCT | 53 (79.1%) | 9 (81.8%) | 1 |
| Bridging therapy | 37 (55.2%) | 8 (80.0%) | .255 |
| Prior anti BCMA exposure | 10 (15.4%) | 0 (0.0%) | .361 |
| Refractory status | .021 | ||
| Double refractory | 2 (3.0%) | 3 (27.3%) | |
| Triple refractory | 36 (53.7%) | 4 (36.4%) | |
| Penta refractory | 26 (38.8%) | 4 (36.4%) | |
| Κ LC value (mg/dL) | 76.0 (10.7-446.3) | 1.8 (1.4-12.1) | .013 |
| Λ LC value (mg/dL) | 2.9 (1.6-12.5) | 1048.4 (2.3-1553.2) | .023 |
| Serum M spike value (g/dL) | 0.6 (0.2-1.6) | 0.4 (0.0-2.8) | .657 |
| Baseline ferritin (ng/mL) | 327.0 (90.0-830.5) | 730.0 (502.0-3575.0) | .028 |
| Baseline CRP (μg/mL) | 0.8 (0.2-3.3) | 0.9 (0.7-3.9) | .455 |
| Fluid overload post lymphodepletion | 6 (9.0%) | 2 (18.2%) | .690 |
Data are presented as mean ± SD, median (interquartile range), or number (percentage), depending on the type of data.
P < .05 is bolded.
High-risk cytogenetics when any of following cytogenetics are present: del(17p), t(4;14) or t(14;16).
High BM burden was defined as ≥ 50% CD138-positive plasma cells in baseline ide-cel bone marrow core biopsy specimen.
Double-refractory disease: refractory to an immunomodulatory agent (IMiD) and proteasome inhibitor (PI).
Triple-refractory disease: refractory to an IMiD, PI, and an anti-CD38 monoclonal antibody.
Penta-refractory disease: refractory to lenalidomide, pomalidomide, bortezomib, carfilzomib, and daratumumab or isatuximab.
All multiple myeloma LC subtype means light-chain subtype for all patients with multiple myeloma (n = 78). Light-chain disease LC subtype means light-chain subtype for only light-chain subtype of multiple myeloma (n = 18 total).
IgH/CCND1 gene rearrangement, which is also called t(11;14). t(11;14) percentage mosaicism means the percentage of cells with loss of one IgH signal and gain of one CCND1 signal.
BM, bone marrow; CRP, C-reactive protein; FISH, fluorescent in situ hybridization; HSCT, hematopoietic stem cell transplant; IgH, immunoglobulin heavy chain; LC, light-chain; R-ISS, Revised International Staging System.